Baird raised the firm’s price target on Voyager Therapeutics (VYGR) to $18 from $15 and keeps an Outperform rating on the shares. The firm noted they entered into an additional collaboration agreement with Novartis (NVS) to leverage the TRACER capsids to develop gene therapies for HD and SMA. Voyager will receive $100M upfront, up to $1.2B in milestones, and tiered royalties.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VYGR:
- Voyager (NASDAQ:VYGR) Skyrockets on ~$1.3B Licensing Deal with Novartis
- Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
- Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
- Voyager Therapeutics selects development candidate for SOD1 program
- Voyager Therapeutics management to meet with Oppenheimer
